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Abstract 
Purpose: To evaluate the effect of a traditional Chinese medicine, Jing Tong Yu Shu (JTYS) on 
endometriosis in a rat surgical model. 
Methods: Endometriosis was induced in 40 female rats. The rats were randomly divided into 4 groups: 
three JTYS groups given different doses of the drug, and a saline group. After four weeks of treatment 
with JTYS, the volume of the endometriotic explants was measured, and the levels of IL-1β and IL-6 in 
peritoneal fluid and serum were determined by enzyme-linked immunosorbent assay (ELISA). The 
production of cytokine IL-1β and IL-6 by peritoneal macrophages was also measured for each group.  
Results: JTYS treatment brought about regression of implants and inhibition of IL-1β and IL-6 
production in a dose-dependent manner, with high-dose JTYS eliciting 66.76 % reduction in mean 
endometriotic explant volume. Plasma and peritoneal fluid levels of IL-1β and IL-6 were significantly 
lower in the high-dose JTYS group than in the saline group (p < 0.05). However, JTYS treatment 
significantly inhibited IL-1β and IL-6 production in peritoneal macrophages (p < 0.05). 
Conclusion: These results suggest that JTYS treatment leads to regression of endometriotic lesions in 
rat. Thus, JTYS has the potential to be developed into a new drug for the treatment of endometriosis.  
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 Endometriosis (EMs), defined by the presence 
of proliferative endometrial tissue outside the 
uterine cavity, is a common and serious illness 
affecting women in their reproductive years [1]. 
The current treatment approaches for 
endometriosis, which are dependent on the fact 
that it is an estrogen-associated disease, may 
cause unwanted side effects. Thus, there is need 
to develop new strategies for endometriosis 
treatment. Endometriosis is a disease associated 
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with inflammation and activation of immune cells 
in the peritoneal environment [2,3]. Inflammatory 
responses during endometriosis depend on 
activated peritoneal fluid macrophages (PMs) [4]. 
Activated PMs can release a variety of cytokines, 
such as interleukin (IL)-1β and IL-6, into the 
peritoneal fluid and serum. These cytokines are 
involved in the pathophysiology of endometriosis 
[5-7]. 
 
A previous meta-analysis [8] has revealed that 
Chinese herbal medicine may be more effective, 
and may have fewer side effects than 
conventional strategies, in endometriosis 
treatment. The traditional Chinese medicine Jing 
Tong Yu Shu (JTYS) consists of eleven herbs: 
Dioscorea polystachya, Corydalis yanhusuo, 
Faeces trogopterori, Paeonia lactiflora Pallas, 
Radix cyathulae, Angelica sinensis, Whitmania 
pigra Whitman, Cornus officinalis, Foeniculi 
Fructus, Cortex cinnamom and Asarum sieboldii. 
In the present study, the effect of JTYS on 




Animals and reagents 
 
Adult female Sprague-Dawley rats (mean body 
weight 200 ± 10 g) were used. All rats were 
housed under a standard 12 h light: 12 h dark 
cycle, and maintained under standard conditions 
for one week to observe their health condition 
before the experiment. The study was approved 
by the Animal Ethic Committee of Harbin 
University of Commerce (Approval ref no. 
2016185). The animal experiments were in full 
compliance with the Principles of Laboratory 
Animal Care (NIH publication no. 85-23, revised 
1985). The dosage of JTYS for an adult human is 
comprised of the following: 20 g Dioscorea 
polystachya, 20 g Corydalis yanhusuo, 12 g 
Faeces trogopterori, 12 g Paeonia lactiflora 
Pallas, 15 g Radix cyathulae, 15 g Angelica 
sinensis, 3 g Whitmania pigra Whitman, 15 g 
Cornus officinalis, 10 g Foeniculi fructus, 10 g 
Cortex cinnamomi, and 5 g Asarum sieboldii. 
These eleven herbs were purchased from LBX 
Drugs (Harbin, Heilongjiang). The equivalent 
dose (D) for the rat was calculated as in Eq 1. 
 
D = (A/S)6.3R ……………… (1) 
 
where A, S and R are adult human dose, 
standard adult human weight and rat weight, 
respectively. This was taken as medium dose for 
rats. The low and high doses of JTYS were half 
and twice the medium dose, respectively. The 
herbs were mixed and kept in water for 1 h, after 
which they were boiled continuously for 30 min. 
The resultant residue was decocted for another 
30 min, and the two decoctions were pooled and 




A rat model of endometriosis was surgically 
produced as described previously, with slight 
modifications [10]. The rats were anesthetized 
with chloral hydrate (350 mg/kg). After routine 
disinfection of each rat skin, the abdominal cavity 
was opened and the uterus was exposed under 
sterile conditions. One centimeter-long distal 
segment was resected from the right uterus and 
was split longitudinally, revealing the 
endometrium. A 5 × 5 mm piece was sectioned 
and implanted onto the peritoneal surface of the 
right abdominal wall. Sham operations were 
performed in another 10 rats. During the 
operation, saline was used to keep the peritoneal 
cavity moist. The abdominal incision was closed 
at the end of the surgery. 
 
Three weeks after the surgery, a second 
operation was performed to observe the ectopic 
endometrium and check whether the 
endometriosis model was successfully 
established. The volume of implant (V) was 
calculated as in Eq 2. 
 
V (mm3) = (π/6)LWH ………….. (2) 
 
where L, W and H are the length, width and 
height of the implant. 
 
The rats with endometriosis were randomly 
divided into four groups (n = 10): Group 1 was 
the EMs group without medication (EMs group); 
Groups 2, 3 and 4 rats were treated with JTYS at 
low, medium and high doses, respectively. The 
extract was given once a day via intra-gastric 
administration for four weeks. After 4 weeks of 





Rats were sacrificed after 4-week treatment. 
After routine disinfection of each rat’s skin, 
peritoneal fluid was collected under sterile 
conditions through rinsing of the peritoneal cavity 
with 2 ml sterile saline. The peritoneal fluid was 
centrifuged at 500 g for 10 min, and the 
supernatant was stored at −80 °C until analysis. 
The peritoneal fluid macrophages were enriched 
by centrifugation using Ficoll-Hypaque (Sigma-
Aldrich, St. Louis, USA) as reported previously 
[11,12], and cultured in 48-well plates for 24 h. 
After 24 h of in vitro culture, the conditioned 
media and macrophages were obtained and 
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stored at −80 °C until analysis. Blood samples 
were centrifuged after collection, and the serum 
samples were frozen at −80 °C until analysis. 
The volume of the implants from EMs rats was 
computed as in Eq 2 above. 
 
In vitro culture of peritoneal fluid 
macrophages 
 
The peritoneal fluid macrophages were cultured 
in RPMI1640 complete medium containing 15 % 
FCS. After attachment for 24h, the cells were 
washed with complete medium and stimulated by 
serum from JTYS- or saline-treated EMs rats for 
another 24 h. Cells in the control group were 
cultured in complete medium. Peritoneal fluid 
macrophage activation was achieved through the 
addition of 10 ng/mL lipopolysaccaride (LPS) 
(Sigma-Aldrich, St. Louis, USA) in the cell culture 
system. The conditioned media and 
macrophages were collected and frozen at −80 
°C until analysis. 
 
Assay of IL-1β and IL-6 using ELISA   
 
The levels of IL-1β and IL-6 were assayed using 
a commercial ELISA kit (Abcam, Cambridge, UK) 
according to the manufacturer’s instructions. 
 
Western blotting for IL-1β and IL-6 
 
Western blot analysis of IL-1β and IL-6 was 
performed using mouse anti-rat IL-6 monoclonal 
antibody (Abcam, Cambridge, UK) and rabbit 
anti-rat IL-1β polyclonal antibody (Abcam, 
Cambridge, UK). β-Actin was used as loading 
control. Immunocomplexes were visualized using 
enhanced chemiluminescence (Cell Signaling 




All data are presented as mean ± standard 
deviation (SD). Mann-Whitney U test was used 
for statistical analysis with the aid of SPSS 





JTYS treatment induced regression of ectopic 
endometrial explants in a rat model of 
endometriosis  
 
Viable implants were observed in 36 out of the 
40 rats. As shown in Table 1, after 4-week 
treatment with saline, mean explant volumes in 
pre-treatment and post-treatment were similar 
(45.73 ± 17.77 mm3 and 47.78 ± 16.51 mm3, 
respectively, p > 0.05). However, JTYS treatment 
significantly decreased the mean explant volume, 
relative to pre-treatment: low dose (49.26 ± 18.45 
mm3 versus 35.46 ± 12.57 mm3, p < 0.05); 
medium dose (43.07 ± 15.53 mm3 versus 20.13 
± 9.77 mm3, p < 0.01) and high dose (46.99 ± 
16.24 mm3 versus 15.55 ± 8.75 mm3, p < 0.01). 
The implant volume was inhibited by 20.56 %, 
53.39% and 66.76% in the low dose, medium 
dose and high dose groups, respectively. 
 
JTYS treatment inhibited the production of 
inflammation-associated cytokines in 
endometriosis  
 
The serum and peritoneal fluid levels of 
inflammatory cytokines IL-1β and IL-6 were 
tested first. Using ELISA, it was found that IL-1β 
and IL-6 levels increased significantly (p < 0.01) 
in EMs rats, when compared with the Sham 
group. However, the production of IL-1β and IL-6 
was down-regulated in the JTYS group 
(especially the high dose group). These results 
are shown in Figure 1. 
 
JTYS treatment inhibited IL-1β and IL-6 
production by peritoneal fluid macrophages  
 
The production of IL-1β and IL-6 by peritoneal 
fluid macrophages was significantly increased in 
the macrophage lysates and their conditioned 
media, as revealed by western blotting and 
ELISA, respectively. More importantly, JTYS 
treatment depressed the production of IL-1β and 
IL-6 by peritoneal fluid macrophages in a dose-
dependent manner (Figure 2). 
 












% Inhibition  
 
EMs 45.73 ± 17.77 47.78 ± 16.51 -2.11 ± 3.22 - 
Low dose  49.26 ± 18.45 35.46 ± 12.57* 10.13 ± 6.99 20.56 
Medium dose  43.07 ± 15.53 20.13 ± 9.77** 23.08 ± 11.67 53.59 
High dose  46.99 ± 16.24 15.55 ± 8.75** 31.37 ± 15.49 66.76 
 Values are expressed as mean ± SD; *p < 0.05, compared with pre-treatment; **p < 0.01, compared with pre-
treatment 




Figure 1: Serum and peritoneal fluid levels of inflammatory cytokines in sham and EMs rats. Serum levels of IL-
1β (A) and IL-6 (B), together with peritoneal fluid levels of IL-1β (C) and IL-6 (D) were quantified by ELISA; ##p < 
0.01, compared with sham; *p < 0.05, compared with EMs; **p < 0.01, compared with EMs 
 
 
Figure 2: IL-1β and IL-6 production by peritoneal fluid macrophages. IL-1β (A) and IL-6 (B) levels in macrophage 
conditioned media were determined by ELISA. Western blot analysis was also carried out to determine the IL-1β 
and IL-6 production in PBS-washed macrophage lysates (C); ##p < 0.01, compared with sham; *p < 0.05, 
compared with EMs; **p < 0.01, when compared with Ems 
 
JTYS suppressed IL-1β and IL-6 production 
by activated peritoneal fluid macrophages  
 
Peritoneal fluid macrophages were isolated from 
untreated rats, and their levels of IL-1β and IL-6 
levels were measured after in vitro culture, with 
or without activation. To rule out any influences 
due to differences in initial status of peritoneal 
fluid macrophages, these cells were obtained 
from untreated rats, but not from rats with 
endometriosis. Irrespective of activation status, 
IL-1β and IL-6 secretions were detected. 
However, LPS activation significantly (p < 0.01) 
elevated the secretions of IL-1β and IL-6 by 
these cells, relative to control (Figure 3). Direct in 
vitro stimulation of LPS-activated peritoneal fluid 
macrophages by serum from JTYS-treated EMs 
rats resulted in approximately 1.5- to 2-fold 
decreases in IL-1β and IL-6 secretions. Thus, 
JTYS treatment directly suppressed the 
production of IL-1β and IL-6 in activated 
peritoneal fluid macrophages. These results are 
depicted in Figure 3. 
 





Figure 3: IL-1β and IL-6 production from LPS-activated and/or JTYS-stimulated peritoneal fluid macrophages. 
The peritoneal fluid macrophages were isolated from rats without endometriosis. These macrophages were 
cultured without special treatment, or activated by LPS (10 ng/ml) together with serum from saline- or JTYS-
treated rats for 24 h. The levels of IL-1β (A) and IL-6 (B) in the conditioned media were determined by ELISA. 
Western blot analysis was carried out to determine the production of IL-1β and IL-6 in PBS-washed macrophages 




Previous clinical data show that JTYS has 
significant protective effects against 
endometriosis. Rat models of endometriosis are 
regarded as useful tools for testing potential 
therapeutic agents, and for understanding the 
pathophysiology of endometriosis [13,14]. In the 
present study, it was shown that the volume of 
ectopic endometriotic implants was decreased by 
JTYS treatment in a surgically induced 
endometriosis rat model. 
 
Inflammatory mediators secreted by peritoneal 
macrophages play important roles in the 
pathophysiology of endometriosis [15,16]. 
Inflammatory cytokine IL-1β is significantly 
involved in the regulation of inflammation and 
immune responses. It has been revealed that IL-
1β can function as angiogenic factor [17] and 
increase sICAM-1 shedding from endometrial 
cells [18], thereby contributing to the 
pathophysiology of endometriosis. IL-6 is a 
multifunction cytokine which is known to induce 
VEGF expression, and to exhibit angiogenic 
effects [19]. This implies the involvement of IL-6-
secreting macrophages in promotion of 
vascularity during endometriosis. The results of 
the present study revealed that JTYS treatment 
significantly decreased the levels of IL-1β and IL-
6 in peritoneal fluid and serum. Thus, the 
therapeutic effect of JTYS on endometriosis 
might be supported by the suppressed 
production of IL-1β and IL-6 by activated 
peritoneal fluid macrophages. 
 
However, it should be noted that IL-1β and IL-6 
can also be produced by other cell types apart 
from peritoneal fluid macrophages. In addition, 
other important inflammatory factors and immune 
cells are involved in the pathophysiology of 
endometriosis [20,21]. Therefore, it will be 
necessary to investigate other possible 
mechanisms underlying the therapeutic effects of 




The results obtained in this investigation suggest 
that JTYS is a potential treatment strategy for 
endometriosis. The underlying mechanisms of 
action of JTYS most likely involve its anti-
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inflammatory action and its ability to decrease 
the size of ectopic endometriotic implants. 
However, further studies are required to 
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